Fotemustine for Non-Small-Cell Lung Cancer
Author Information
Author(s): J.-L. Pujol, A. Monnier, J. Berille, M.-L. Cerrina, J.-Y. Douillard, A. Riviere, A. Grandgirard, S. Gouva, J.-P. Bizzari, T. Le Chevalier
Primary Institution: Service des Maladies Respiratoires, Universite de Montpellier
Hypothesis
Can fotemustine be an effective single-drug chemotherapy for poor-prognosis non-small-cell lung cancer?
Conclusion
Fotemustine is a feasible and manageable treatment option for patients with poor-prognosis non-small-cell lung cancer.
Supporting Evidence
- 13 out of 77 evaluable patients had an objective response.
- 60% of patients had received prior chemotherapy.
- Quality of life remained stable for responding patients.
Takeaway
Fotemustine is a medicine that can help some people with a type of lung cancer, even if their situation is not very good.
Methodology
Patients received fotemustine 100 mg/m2 on days 1 and 8, followed by a 5-week rest, with maintenance therapy every 3 weeks for responders.
Potential Biases
Potential bias due to the inclusion of pretreated patients and those with brain metastases.
Limitations
The study included a small sample size and was limited to patients with specific characteristics.
Participant Demographics
Median age was 60 years, with 66 males and 21 females; 74% had metastatic disease.
Statistical Information
P-Value
p<0.05
Confidence Interval
95% CI 9-25%
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website